Hypothesis: Age-related fragmentation of hyaluronic acid generates low-molecular-weight fragments (LMW-HA) that activate TLR2 on dermal fibroblasts. This triggers NLRP3 inflammasome assembly and caspase-1-dependent IL-1β secretion. The secreted IL-1β acts in an autocrine/paracrine fashion to establish a self-perpetuating inflammatory loop: it reinforces HAS2 transcriptional repression through sustained ERK1/2 nuclear exclusion, and it induces epigenetic silencing of HAS2 via histone deacetylase recruitment or DNA methyltransferase activation. Once established, this pro-inflammatory state becomes self-sustaining—even after the initial LMW-HA is cleared.

Mechanistic Rationale: Previous studies showed that collagen fragments suppress HAS2 via ERK1/2 blockade, and LMW-HA triggers TLR2-NF-κB signaling. However, the downstream inflammasome activation and epigenetic consequences haven't been characterized. Tissue-specific dominance of TLR2 over TLR4/CD44 in disc cells [PMC3978638] suggests this pathway may be conserved in fibroblasts. NLRP3 links systemic inflammation to aging [Cell Metab 2013], and LMW-HA activates both MAPK and NF-κB [PMC3978638], so these pathways likely converge on NLRP3. The resulting IL-1β release could amplify inflammatory transcription while recruiting epigenetic machinery—HDAC1/2 or DNMT1—to the HAS2 promoter. This would explain why HAS2 downregulation becomes irreversible in aged dermis.

Testable Predictions:

1. In vitro: Treating primary dermal fibroblasts with LMW-HA (<10 kDa) will induce NLRP3 ASC speck formation, caspase-1 activation, and IL-1β secretion (ELISA/Western blot). TLR2 siRNA or NLRP3 inhibition (MCC950) should abolish this response.
2. Mechanistic: Blocking IL-1β signaling (anakinra) or IL-1R1 knockout will prevent LMW-HA-induced HAS2 suppression and restore ERK1/2 nuclear localization.
3. Epigenetic: ChIP-qPCR will show increased DNMT3B or HDAC1 occupancy at the HAS2 promoter after LMW-HA/IL-1β exposure, with corresponding loss of histone H3K9/27 acetylation or gain of methylation.
4. Therapeutic: Combining a HAS2 transcriptional activator (e.g., PDE4 inhibition to boost cAMP/ERK) with NLRP3 inhibition will synergistically restore high-MW HA synthesis in aged fibroblast cultures, producing effects beyond what either agent achieves alone.

Falsifiability: The hypothesis fails if LMW-HA doesn't activate NLRP3 in fibroblasts despite robust TLR2 signaling, or if IL-1β blockade doesn't restore HAS2 expression. Similarly, if epigenetic inhibitors (5-azacytidine/HDACi) can't reactivate HAS2 without targeting the upstream inflammasome, the feedforward model needs revision.

Therapeutic Implication: Breaking the scaffold-to-toxin cycle in aged skin likely requires restoring endogenous high-MW HA synthesis rather than just supplementing it, combined with inflammasome inhibition.